SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
0269881106060967v1
20/5/683    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Zuardi, A. W.
Right arrow Articles by Crippa, J. A.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zuardi, A. W.
Right arrow Articles by Crippa, J. A.S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Schizophrenia
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Cannabidiol monotherapy for treatment-resistant schizophrenia

Antonio W. Zuardi1*, Jamie E.C. Hallak1, Serdar Murat Dursun2, Silvio L. Morais1, Rafael Faria Sanches1, Richard E. Musty3, Jose A.S. Crippa1

1 Department of Neuropsychiatry and Medical Psychology, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
2 Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
3 Department of Psychology, University of Vermont, Burlington, USA

* To whom correspondence should be addressed.


  Abstract
Cannabidiol (CBD), one of the major products of the marijuana plant, is devoid of marijuana's typical psychological effects. In contrast, potential antipsychotic efficacy has been suggested based on preclinical and clinical data (Zuardi et al., 2002). In this report, we further investigated the efficacy and safety of CBD monotherapy in three patients with treatment-resistant schizophrenia (TRS). This was an in-patient study. All patients were given placebo for the initial 5 days, and from the 6th to 35th day (inclusive) they received CBD (initial oral dose of 40 mg reaching 1280 mg/day). On day 36th, CBD treatment was discontinued and replaced by placebo for 5 days, which was subsequently switched to olanzapine for over 15 days. Efficacy, tolerability and side effects were assessed. One patient showed mild improvement, but two patients didn't show any improvement during CBD monotherapy. All patients tolerated CBD very well and no side effects were reported. These preliminary data suggest that CBD monotherapy may not be effective for TRS.

Key Words: cannabidiol, CBD, schizophrenia, psychosis, treatment

First published on January 9, 2006, doi:10.1177/0269881106060967

Journal of Psychopharmacology 2006;20:683.

A more recent version of this article appeared on September 1, 2006

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
A. Zuardi, J. Crippa, J. Hallak, J. Pinto, M. Chagas, G. Rodrigues, S. Dursun, and V. Tumas
Cannabidiol for the treatment of psychosis in Parkinson's disease
J Psychopharmacol, November 1, 2009; 23(8): 979 - 983.
[Abstract] [PDF]


Advertisement